A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C9*24) ina patient on warfarin therapy

Darja Herman; Polona Peternel; Mojca Stegnar; Katja Breskvar; Vita Dolzan

doi:10.1055/s-0037-1612583

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2006; 95(01): 192-194
DOI: 10.1055/s-0037-1612583

Case Report

Schattauer GmbH

A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C9*24) ina patient on warfarin therapy

Darja Herman

¹Institute of Biochemistry, Faculty of Medicine, Ljubljana, Slovenia

,

Polona Peternel

²University Medical Centre, Department for Vascular Diseases, Ljubljana, Slovenia

,

Mojca Stegnar

²University Medical Centre, Department for Vascular Diseases, Ljubljana, Slovenia

,

Katja Breskvar

¹Institute of Biochemistry, Faculty of Medicine, Ljubljana, Slovenia

,

Vita Dolzan

¹Institute of Biochemistry, Faculty of Medicine, Ljubljana, Slovenia

References
1 Xie HG, Prasad HC, Kim RB. et al. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54: 1257-70.
2 Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74.
3 Rettie AE, Wienkers LC, Gonzalez FJ. et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 04: 39-42.
4 Sullivan-Klose TH, Ghanayem BI, Bell DA. et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 06: 341-9.
5 Takahashi H, Echizen H. Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics 2003; 03: 202-14.
6 Herman D, Locatelli I, Grabnar I. et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 2005; 05: 193-202.
7 Rost S, Fregin A, Ivaskevicius V. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-41.
8 Li T, Chang CY, Jin DY. et al. Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427: 541-4.
9 D’Andrea G, D’ambrosio RL, Di Perna P. et al. A polymorphism in VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-9.
10 Bodin L, Verstuyft C, Tregouet DA. et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135-40.
11 Yuan HY, Chen JJ, Lee MT. et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745-51.
12 Rieder MJ, Reiner AP, Gage BF. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-93.
13 Imai J, Ieiri I, Mamiya K. et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 2000; 10: 85-9.
14 Locatelli I, Kmetec V, Mrhar A. et al. Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 818: 191-8.
15 Stephens M, Smith N, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-89.
16 Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162-9.
17 Kates RE, Yee YG, Kirsten EB. Interaction between warfarin and propafenone in healthy volunteer subjects. Clin Pharmacol Ther 1987; 42: 305-11.